BD PharmingenTM PE Mouse Anti-Human IL-12 (p40/p70)

Description

Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls. Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls. Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls. Show More Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls. Show More Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls. Expression of IL-12 p40/p70 by HiCK-3 cells. Ficoll-separated human PBMCs were primed for 2 hours with recombinant human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616 , then activated with IFN-gamma 20 ng/ml final concentration and LPS 1 mug/ml final concentration; Sigma in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 for an additional 22 hours. Cells were harvested, fixed, permeabilized, and then stained with 20 mul of PE-C11.5 antibody Cat. No. 559329 , by following the Usage section above and Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-C11.5 antibody was blocked by preincubation of the conjugated antibody with an excess of the unlabelled C11.5 antibody 5 mug, Cat. No. 554573; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabelled antibody blocking specificity controls.